1. Home
  2. COSM vs APRE Comparison

COSM vs APRE Comparison

Compare COSM & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cosmos Health Inc.

COSM

Cosmos Health Inc.

HOLD

Current Price

$0.22

Market Cap

12.9M

Sector

Health Care

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.83

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COSM
APRE
Founded
2009
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
11.5M
IPO Year
2009
2019

Fundamental Metrics

Financial Performance
Metric
COSM
APRE
Price
$0.22
$0.83
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.10
AVG Volume (30 Days)
2.7M
381.5K
Earning Date
04-15-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
46.15
21.22
EPS
N/A
N/A
Revenue
$65,271,815.00
N/A
Revenue This Year
$54.08
N/A
Revenue Next Year
$32.66
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.93
N/A
52 Week Low
$0.16
$0.55
52 Week High
$1.32
$1.69

Technical Indicators

Market Signals
Indicator
COSM
APRE
Relative Strength Index (RSI) 47.44 N/A
Support Level $0.17 N/A
Resistance Level $0.28 N/A
Average True Range (ATR) 0.02 0.00
MACD 0.00 0.00
Stochastic Oscillator 44.37 0.00

Price Performance

Historical Comparison
COSM
APRE

About COSM Cosmos Health Inc.

Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: